Skip to content
Screener

PP&E (Net) at other companies

ALN
Alnylam PharmaceuticalsALNY
$554.14M+10.9%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$15.06M-34.0%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$112.18M-13.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$23.68M+312%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$1.08M-44.6%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$2.41M-65.3%

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$896.8M+227%
Enterprise value$886.76M+245%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063
Line itemMarch 31, 2026December 31, 2025
Investment securities210,053202,989
Prepaid expenses and other current assets4,2263,939
Total current assets227,049223,784
Property and equipment, net824981
Right-of-use asset2,5691,438
Total assets$230,442$226,203
Liabilities and Stockholders’ Equity
Current liabilities:

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s PP&E (net)?
Design Therapeutics, Inc. (DSGN) reported PP&E (net) of $824K in Q1 2026.
How has Design Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Design Therapeutics, Inc.'s PP&E (net) decreased by 40.2% year-over-year, from $1.38M to $824K.
What is the long-term trend for Design Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s PP&E (net) has grown at a 69.1% compound annual growth rate (CAGR), from $71K to $981K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Design Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude